Radiopharmaceutical development is accelerating. Preclinical...
Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Newsletters and Deep Dive digital magazine
Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.
One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
Ongoing work in Morocco demonstrates how developing research infrastructure can support innovative approaches grounded in locally generated data.
In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Editor's Picks
Newsletters and Deep Dive
digital magazine